Literature DB >> 12751995

Interstitial lung disease in systemic sclerosis.

G C Ooi1, M Y Mok, K W T Tsang, Y Wong, P L Khong, P C W Fung, S Chan, H F Tse, R W S Wong, W K Lam, C S Lau.   

Abstract

PURPOSE: To evaluate high-resolution CT (HRCT) parameters of inflammation and fibrosis in systemic sclerosis (SSc), for correlation with lung function, skin scores and exercise tolerance.
MATERIAL AND METHODS: 45 SSc patients (40 women, 48.5+/-13.4 years), underwent thoracic HRCT, lung function assessment, and modified Rodnan skin scores. Exercise tolerance was also graded. HRCT were scored for extent of 4 HRCT patterns of interstitial lung disease (ILD): ground glass opacification (GGO), reticular, mixed and honeycomb pattern in each lobe. Total HRCT score, inflammation index (GGO and mixed score) and fibrosis index (reticular and honeycomb scores) were correlated with lung function and clinical parameters.
RESULTS: ILD was present in 39/45 (86.7%) patients. Abnormal (<80% predicted) forced vital capacity (FVC), total lung capacity (TLC) and carbon monoxide diffusion factor (DLco) were detected in 30%, 22% and 46% of patients. Total HRCT score correlated with FVC (r=-0.43, p=0.008), FEV1 (forced expiratory volume) (r=-0.37, p=0.03), TLC (r=-0.47, p=0.003), and DLCO (r=-0.43, p=0.008); inflammatory index with DLCO (r=-0.43, p=0.008) and exercise tolerance (r=-0.39, p < 0.05); and fibrosis index with FVC (r=-0.31, p=0.05) and TLC (r=-0.38, p=0.02). Higher total HRCT score, and inflammation and fibrosis indices were found in patients with abnormal lung function.
CONCLUSION: Qualitative HRCT is able to evaluate inflammation and fibrosis, showing important relationships with diffusion capacity and lung volume, respectively.

Entities:  

Mesh:

Year:  2003        PMID: 12751995     DOI: 10.1080/j.1600-0455.2003.00058.x

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.701


  21 in total

1.  Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis.

Authors:  Shiko Kuribayashi; Sei-Ichiro Motegi; Kenichiro Hara; Yasuyuki Shimoyama; Hiroko Hosaka; Akiko Sekiguchi; Kouichi Yamaguchi; Osamu Kawamura; Takeshi Hisada; Osamu Ishikawa; Motoyasu Kusano; Toshio Uraoka
Journal:  J Gastroenterol       Date:  2019-04-01       Impact factor: 7.527

2.  The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.

Authors:  Hyo Jin Choi; Young Kee Shin; Hyun Joo Lee; Joo Young Kee; Dong Woo Shin; Eun Young Lee; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Clin Rheumatol       Date:  2007-09-25       Impact factor: 2.980

Review 3.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

4.  Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis.

Authors:  Robert K McCall; James G Ravenel; Paul J Nietert; Aleksandra Granath; Richard M Silver
Journal:  J Comput Assist Tomogr       Date:  2014 Mar-Apr       Impact factor: 1.826

Review 5.  Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study.

Authors:  Kristin B Highland; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

6.  Lung scintigraphy with nonspecific human immunoglobulin G ((99m)Tc-HIG) in the evaluation of pulmonary involvement in connective tissue diseases: correlation with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT).

Authors:  Ch Kostopoulos; J Koutsikos; C Toubanakis; L A Moulopoulos; Ch Mamoulakis; E Gialafos; P P Sfikakis; Ch Zerva; M Mavrikakis; A Leondi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-06       Impact factor: 9.236

7.  Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

Authors:  Charlie Strange; Marcy B Bolster; Michael D Roth; Richard M Silver; Arthur Theodore; Jonathan Goldin; Philip Clements; Joanie Chung; Robert M Elashoff; Robert Suh; Edwin A Smith; Daniel E Furst; Donald P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

8.  Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia.

Authors:  Kota Murohashi; Yu Hara; Yusuke Saigusa; Nobuaki Kobayashi; Takashi Sato; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

9.  Deep Learning-based Approach for Automated Assessment of Interstitial Lung Disease in Systemic Sclerosis on CT Images.

Authors:  Guillaume Chassagnon; Maria Vakalopoulou; Alexis Régent; Evangelia I Zacharaki; Galit Aviram; Charlotte Martin; Rafael Marini; Norbert Bus; Naïm Jerjir; Arsène Mekinian; Thông Hua-Huy; Laurence Monnier-Cholley; Nouria Benmostefa; Luc Mouthon; Anh-Tuan Dinh-Xuan; Nikos Paragios; Marie-Pierre Revel
Journal:  Radiol Artif Intell       Date:  2020-07-15

Review 10.  The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.